Rapid Oral Abstract (Abstract 632): Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial
Poster presentation (Abstract 593): Blue Light Cystoscopy versus White Light Cystoscopy for the Detection of Bladder Cancer in China: An Analysis of Unpublished Clinical Trial and Real-World Data
Bladder cancer is the tenth-most commonly diagnosed cancer worldwide, with approximately 573,000 new cases and 213,000 deaths annually1; of these, MIBC represents approximately 20% of newly diagnosed cases2.
The recommended standard of care for MIBC is radical cystectomy (RC) with bilateral pelvic lymph node dissection, preceded by the administration of neoadjuvant chemotherapy (NAC) in patients who are eligible to receive cisplatin3. However, approximately 50% of the patients are cisplatin-ineligible because of pre-existing contraindications, and some refuse to receive any chemotherapy4,5. Currently, there are still many challenges that need to be addressed in the treatment of MIBC.
The interim analysis of ANTICIPATE data, to be presented at the 2024 ASCO-GU, indicates that the combination of APL-1202 with the PD-1 inhibitor, tislelizumab, shows promising therapeutic potential as neoadjuvant treatment for MIBC patients. This combination therapy holds promise as a treatment option for MIBC patients who are platinum-intolerant or refuse platinum-based therapy.
It is worth mentioning that the ANTICIPATE trial protocol of the oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in MIBC patients was previously selected as a poster presentation at the 2022 ASCO Annual Meeting. The Phase I clinical data was first disclosed at the 2023 ASCO the following May and in September of this year, the interim analysis of its Phase II study was completed, showing signs of positive outcome.
In addition to the registration trial data presentation of APL-1706 at the 2023 Société Internationale d’Urologie (SIU) Annual Meeting, data of the Real-World Study (RWS) will be presented for the first time at the 2024 ASCO-GU as a poster and will be compared to the registration trial data.
References:
- Sung H, et al.CA Cancer J Clin 2021; 71: 209-49.
- Patel VG, et al.CA Cancer J Clin 2020; 70: 404-23.
- Alfred Witjes J,et al. Eur Urol 2017; 71: 462-75.
- Galsky MD, et al. J Clin Oncol 2011; 29: 2432-8.
- Burger M, et al.Eur Urol 2012; 61: 1070-1.